A strong stock as of late has been Puma Biotech (PBYI) . Shares have been marching higher, with the stock up 40.6% over the past month. The stock hit a new 52-week high of $5.06 in the previous session. Puma Biotech has gained 59% since the start of the year compared to the -7.5% move for the Zacks Medical sector and the -0.9% return for the Zacks Medical - Biomedical and Genetics industry.What's Driving the Outperformance?The stock has an impressive record of positive earnings surprises, having beaten the ...

Key Takeaways PBYI posted Q2 adjusted EPS of $0.15, beating estimates and reversing the year-ago loss.Nerlynx product sales rose 10.8% year over year to $49.2M, within management's guidance.2025 revenue outlook remains $212M-$222M, with Nerlynx sales expected to be in the range of $192M-$198M.Puma Biotechnology (PBYI) reported second-quarter 2025 adjusted earnings of 15 cents per share, which beat the Zacks Consensus Estimate of 11 cents. In the year-ago quarter, the company had incurred an adjusted loss of ...

Puma Biotechnology (PBYI) Q2 2025 Earnings Call August 07, 2025 04:30 PM ET Speaker0Good afternoon. My name is Latanya, and I will be your conference call operator today. As a reminder, this call is being recorded. I would now like to turn the conference over to your host today, Mary Anne Ohanaisen, Senior Director of IR for Puma Biotechnology. You may begin your conference.Speaker1Thank you, Latanya. Good afternoon and welcome to Puma's conference call to discuss our earnings results for the 2025. Joining ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 10880 Wilshire Boulevard, Suite 2150, Los Angeles, CA 90024 (Address of principal executive offices) (Zip code) (424) 248-6500 (Registrant's telephon ...

LOS ANGELES, Calif., Aug. 7, 2025 - Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2025. Unless otherwise stated, all comparisons are for the second quarter 2025 compared to the second quarter 2024. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma's first commercial product. Product revenue, net in the second quarter of 2025 was $49.2 million, compared to product revenue, net of $44.4 milli ...

Earnings Call Commercial Update August 7, 2025 Puma Biotechnology Forward-Looking Safe-Harbor Statement This presentation contains forward-looking statements, including statements regarding commercialization of NERLYNX® and the potential indications and development of our drug candidates. All forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These sta ...

Core Insights - Puma Biotechnology has an approved drug and decent sales but lacks market appreciation despite its ongoing pipeline [1] Company Overview - Puma Biotechnology is characterized as an "odd duck" in the biotech sector, having a unique position with an approved drug and reasonable sales figures [1] - The company has a continuing pipeline that suggests potential for future growth [1] Analyst Perspective - The author expresses cautious optimism regarding Puma Biotechnology, indicating that there are valid reasons for the current market sentiment [1] - The author has a background in biochemistry and extensive experience in analyzing clinical trials and biotech companies, which informs their perspective on the company [1]

Group 1 - Momentum investing focuses on "buying high and selling higher" rather than traditional "buying low and selling high" strategies [1] - Fast-moving trending stocks can lose momentum if their future growth does not justify their high valuations, leading to potential downside risks for investors [2] - A safer investment strategy involves identifying bargain stocks that exhibit recent price momentum, utilizing tools like the Zacks Momentum Style Score [3] Group 2 - Puma Biotech (PBYI) is highlighted as a strong candidate for momentum investing, with a recent price increase of 3.6% over the past four weeks [4] - PBYI has shown a significant price gain of 13.2% over the past 12 weeks, indicating its potential for sustained positive returns [5] - The stock has a beta of 1.29, suggesting it moves 29% more than the market, indicating fast-paced momentum [5] Group 3 - PBYI has a Momentum Score of B, suggesting it is an opportune time to invest in the stock to capitalize on its momentum [6] - The stock has received a Zacks Rank 2 (Buy) due to upward revisions in earnings estimates, which typically attract more investor interest [7] - PBYI is trading at a Price-to-Sales ratio of 0.71, indicating it is undervalued at 71 cents for each dollar of sales, providing room for growth [7] Group 4 - In addition to PBYI, there are other stocks that meet the criteria for fast-paced momentum at a bargain, which investors may consider [8] - Zacks offers over 45 Premium Screens tailored to different investing styles, aiding in the identification of potential winning stocks [9]

Momentum investing is essentially the opposite of the tried-and-tested Wall Street adage -- "buy low and sell high." Investors following this investing style typically avoid betting on cheap stocks and waiting long for them to recover. They believe instead that one could make far more money in lesser time by "buying high and selling higher."Who doesn't like betting on fast-moving trending stocks? But determining the right entry point isn't easy. Often, these stocks lose momentum once their valuation moves a ...

Core Viewpoint - Puma Biotechnology (PBYI) is currently identified as a strong value stock based on its favorable valuation metrics and earnings outlook [3][7]. Valuation Metrics - PBYI has a PEG ratio of 1.38, significantly lower than the industry average of 2.45, indicating potential undervaluation [4]. - The stock's P/B ratio stands at 1.61, compared to the industry's average of 3.01, suggesting a solid market value relative to its book value [5]. - PBYI's P/CF ratio is 3.53, which is attractive when compared to the industry's average of 12.71, highlighting its strong cash flow outlook [6]. Performance Insights - Over the past 52 weeks, PBYI's PEG ratio has fluctuated between 1.38 and 1.79, with a median of 1.51, indicating stable valuation [4]. - The P/B ratio has ranged from 1.47 to 4.86 in the last 12 months, with a median of 2.04, reflecting variability in market perception [5]. - The P/CF ratio has seen a range from 3.24 to 9.59, with a median of 4.20, further supporting the notion of undervaluation [6].